

## ELCC 2017 Industry Satellite Symposium



# Choices across treatment lines: Maximising patient outcomes in advanced or metastatic NSCLC

Chaired by Luis Paz-Ares

Saturday 6th May 2017  
13:00-14:00, Room A  
Palexpo, Geneva, Switzerland

### Dear Colleagues,

We invite you to join us at this independent symposium, 'Choices across treatment lines: Maximising patient outcomes in advanced or metastatic NSCLC' at the European Lung Cancer Conference.

The aim of this symposium is to provide practical advice for clinicians treating NSCLC in an increasingly intricate therapy landscape. During this session, the expert Faculty will guide the delegates through case studies covering the harder-to-treat squamous NSCLC patient and the increasingly complex problem of what is the best approach for adenocarcinoma patients who rapidly progress. Throughout the case studies we will be asking the audience to vote on which treatment options they would choose at defined points along the patients' therapeutic journey. This will allow the audience to compare their treatment choices with their peers and provide an opportunity for the Faculty to discuss the potential gaps between current common practice and what the latest data suggests would be ideal.

We hope that you find this symposium engaging and informative and that it will further your understanding of this evolving field, providing advice to facilitate decision making in your clinical practice. Accordingly, we aim to provide maximum interaction and discourse between Faculty and audience so that we may work together to optimise patient outcomes.

We hope you will join us. Yours faithfully,

*Luis Paz-Ares*

**Luis Paz-Ares – Chair**

## Programme

Time	Title	Speaker
13:00 – 13:05	Introduction	Luis Paz-Ares Spain
13:05 – 13:30	Individualising treatment options to improve squamous NSCLC patient outcomes	Egbert Smit The Netherlands
13:30 – 13:55	Patient pathways in rapid progression	Benjamin Besse France
13:55 – 14:00	Closing remarks	Luis Paz-Ares Spain

## Learning Objectives

Following attendance at this symposium delegates should be able to:

- Explain the remaining high unmet therapeutic needs for patients with advanced squamous NSCLC in comparison to those with adenocarcinoma
- Describe the optimal treatment path for advanced non-squamous NSCLC patients who rapidly progress during first-line therapy, and highlight the benefits of various therapeutic approaches to maximise individual patient outcomes
- Debate the latest research which could further improve outcomes for patients with NSCLC

An application has been made to the EACCME® for CME accreditation of this event